Given the antileukemic activity of another small molecule CREBBP/EP300 inhibitor (I-CBP112) in AML cells with NUP98 fusions, one may predict that this drug also impairs the formation and/or function of NUP98-fusion protein-containing condensates (Figure 3B).114 Importantly, as condensates can also be induced by functionally impaired NUP98-fusion proteins, CREBBP/EP300 inhibition likely impairs the oncogenic activity of NUP98-fusion through inhibitory effects on condensate constituents rather than on condensate formation per se.62 The gene discussed is CREBBP; the disease is acute myeloid leukemia.